Antibe Therapeutics Overview

  • Status
  • Acquired/​Merged

  • Employees
  • 11

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $161M

Antibe Therapeutics General Information

Description

Antibe Therapeutics Inc is a clinical stage biotechnology company leveraging its proprietary hydrogen sulfide (H2S) platform to develop next-generation therapies to address inflammation arising from a wide range of medical conditions. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Antibe's drug, otenaproxesul, is in development for the treatment of acute and chronic pain. The company's second pipeline drug is a GI-sparing alternative to ketoprofen. The company's next target is inflammatory bowel disease (IBD), a condition long in need of safer, more effective therapies.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 15 Prince Arthur Avenue
  • Toronto, Ontario M5R 1B2
  • Canada
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Corporate Office
  • 15 Prince Arthur Avenue
  • Toronto, Ontario M5R 1B2
  • Canada

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Antibe Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
15. Merger/Acquisition 17-Mar-2025 $161M Completed Generating Revenue
14. Bankruptcy: Admin/Reorg 24-Jun-2024 Completed Bankruptcy: Admin/Reorg
13. 2PO 24-Feb-2021 Completed Generating Revenue
12. PIPE 30-Jun-2020 Completed Generating Revenue
11. PIPE 13-Aug-2019 Completed Generating Revenue
10. PIPE 27-Feb-2019 Completed Generating Revenue
9. PIPE 18-Aug-2017 Completed Generating Revenue
8. PIPE 21-Dec-2016 Completed Generating Revenue
7. PIPE 20-Jun-2016 $1.46M $8.84M Completed Generating Revenue
6. PIPE 01-Apr-2015 $786K $7.38M Completed Generating Revenue
To view Antibe Therapeutics’s complete valuation and funding history, request access »

Antibe Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Antibe Therapeutics Inc is a clinical stage biotechnology company leveraging its proprietary hydrogen sulfide (H2S) plat
Drug Discovery
Toronto, Canada
11 As of 2023

Melbourne, Australia
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Antibe Therapeutics Competitors (8)

One of Antibe Therapeutics’s 8 competitors is Mesoblast, a Corporation company based in Melbourne, Australia.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Mesoblast Corporation Melbourne, Australia
Centrexion Therapeutics Venture Capital-Backed Boston, MA
Surrozen Formerly VC-backed South San Francisco, CA
Lisata Therapeutics Corporation Basking Ridge, NJ
Capricor Therapeutics Formerly VC-backed San Diego, CA
You’re viewing 5 of 8 competitors. Get the full list »

Antibe Therapeutics Patents

Antibe Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025248450-A1 H2s-releasing mesalamine analogs Pending 28-May-2024
WO-2025215470-A1 Amorphous otenaproxesul for the treatment of acute pain Pending 10-Apr-2024
EP-4791713-A1 Polymorphic forms of otenaproxesul and compositions and uses thereof Pending 11-Oct-2023
WO-2025076616-A1 Polymorphic forms of otenaproxesul and compositions and uses thereof Inactive 11-Oct-2023
EP-4784583-A1 Phenylthione-2,3-dihydro-1h-pyrrolizine derivatives and pharmaceutical compositions thereof useful as h2s-releasing ketorolac analogues Pending 29-Sep-2023 A61P29/00
To view Antibe Therapeutics’s complete patent history, request access »

Antibe Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Antibe Therapeutics Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Hero Ventures Corporation Minority
Hero Ventures (Canada) Venture Capital Minority
Verdex Capital Venture Capital Minority
To view Antibe Therapeutics’s complete investors history, request access »

Antibe Therapeutics Investments & Acquisitions (2)

Antibe Therapeutics’s most recent deal was a Corporate with Citagenix for . The deal was made on 02-Feb-2016.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Citagenix 02-Feb-2016 Corporate Surgical Devices
Citagenix 16-Oct-2015 Merger/Acquisition Surgical Devices
To view Antibe Therapeutics’s complete investments and acquisitions history, request access »

Antibe Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Antibe Therapeutics’s complete esg history, request access »

Antibe Therapeutics FAQs

  • Where is Antibe Therapeutics headquartered?

    Antibe Therapeutics is headquartered in Toronto, Canada.

  • What is the size of Antibe Therapeutics?

    Antibe Therapeutics has 11 total employees.

  • What industry is Antibe Therapeutics in?

    Antibe Therapeutics’s primary industry is Drug Discovery.

  • Is Antibe Therapeutics a private or public company?

    Antibe Therapeutics is a Private company.

  • What is the current valuation of Antibe Therapeutics?

    The current valuation of Antibe Therapeutics is .

  • What is Antibe Therapeutics’s current revenue?

    The current revenue for Antibe Therapeutics is .

  • How much funding has Antibe Therapeutics raised over time?

    Antibe Therapeutics has raised $90.8M.

  • Who are Antibe Therapeutics’s investors?

    Hero Ventures, Hero Ventures (Canada), and Verdex Capital have invested in Antibe Therapeutics.

  • Who are Antibe Therapeutics’s competitors?

    Mesoblast, Centrexion Therapeutics, Surrozen, Lisata Therapeutics, and Capricor Therapeutics are some of the 8 competitors of Antibe Therapeutics.

  • When was Antibe Therapeutics acquired?

    Antibe Therapeutics was acquired on 17-Mar-2025.

  • Who acquired Antibe Therapeutics?

    Antibe Therapeutics was acquired by Taro Pharmaceutical Industries.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process